State-of-the-art laboratory
CHDR's cellular laboratory was rebuilt in 2017 almost entirely from scratch. The facilities were upgraded to a dedicated, fully-equipped cell culture lab with space for four technicians. We also acquired an additional flow cytometer, increased the number of flow hoods and incubators, and purchased new equipment, including a fluorescence microscope, a stereo microscope, and ELISA and ELISPOT readers. Combined with bedside laboratory testing and a magnetic cell sorter, our facilities are fully equipped for the study of drug effects at the molecular and cellular levels. CHDR’s R&D laboratory team has also been expanded in recent years.
Facilities and equipment
- Cell culture lab
- Flow cytometer
- Flow hoods
- Fluorescent microscopy
- ELISA
- Magnetic cell sorter
- ELISPOT reader
Capabilities
Cell isolation / sorting
- Magnetic sorting (RoboSep)
Immunophenotyping
- Flow cytometry (MACSQuant)
- Cell surface markers
- Intracelluar cytokines
- Phosphoprotein profiling
Cell incubations / cultures
- Primary cells (whole blood, PBMCs)
- Intended pharmacology – in vitro and ex vivo drug effects
- Unintended pharmacology – Fc-gamma mediated effects (Abs), contamination, endosomal TLRs (oligonucleotides)
Biomarkers in recent studies: examples
Dermatology research
- Disease areas: psoriasis, atopic dermatitis, acne, HPV-mediated conditions
Pathways / mechanisms of action:
· TLR7/8/9 (ex vivo)
· TLR7 (in vivo imiquimod challenge)
· T-cell costimulation
· Antimicrobial peptides
· Immunostimulation by antisense oligonucleotides (ex vivo)
Vascular medicine research
- Disease areas: rheumatoid arthritis, atherosclerosis, pulmonary fibrosis
Pathways / mechanisms of action:
· Inflammasome
· T-cell costimulation
· p38 MAPK
· TLR4
· Serum amyloid P
CNS research
- Disease areas: Parkinson’s, MS, Huntington’s, Alzheimer’s (neurodegeneration), depression
Pathways / mechanisms of action:
· TLR9
· Inflammasome
· Phosphokinases
· Cholinergic pathways
· In vivo myelin turnover
· Mitochondrial function (relevant for neurodegenerative diseases)